Bevacizumab Reduces Epistaxis‐Related Operative Burden in Hereditary Hemorrhagic Telangiectasia
KEY POINTS: Bevacizumab reduced epistaxis-related ablation frequency by 55.6% in HHT patients. Over half of HHT patients (57.7%) required no ablation intervention after bevacizumab initiation. Maintenance bevacizumab dosing remains highly variable, underscoring the need for standardization.
Authors
- Adam J. Kimple (ORCID: https://orcid.org/0000-0003-1670-8401)
- Raj S. Kasthuri (ORCID: https://orcid.org/0000-0001-6672-3082)
- Brent A. Senior (ORCID: https://orcid.org/0000-0002-1503-3150)
- Ezer H. Benaim (ORCID: https://orcid.org/0000-0001-8190-0091)
- Elena Quinonez Del Cid (ORCID: https://orcid.org/0000-0002-4036-6846)
- Brian D. Thorp
- Anna Van Dorsten
- Jackson Vuncannon
- Priya J. Desai
- Nathan R. Barefoot (ORCID: https://orcid.org/0009-0002-2545-1943)
- Katrina Bootes
- Ismail M. Khaderi (ORCID: https://orcid.org/0009-0001-6046-4961)
- Cristine Klatt-Cromwell
- Charles S. Ebert
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- International Forum of Allergy & Rhinology
- Published
- 2026-08-14
- DOI
- https://doi.org/10.1002/alr.70248
- Primary Topic
- Vascular Anomalies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00